Hemorrhagic stroke comprises about 20% of all strokes, with intracerebral hemorrhage
(ICH) being the most common type. Frequency of ICH is increased where hypertension is …

Intravenous recombinant tissue plasminogen activator (r-tPA) was approved for use in acute
ischemic stroke in the United States in 1996. Approximately 2% to 5% of patients with acute …

Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …

Background and Purpose—Symptomatic intracerebral hemorrhage (SICH) is a serious
complication in patients with acute ischemic stroke treated with intravenous thrombolysis …

Delayed thrombolytic treatment with recombinant tissue plasminogen activator (tPA) may
exacerbate blood–brain barrier breakdown after ischaemic stroke and lead to lethal …

Background and purpose Endovascular techniques are frequently employed to treat large
artery occlusion in acute ischemic stroke (AIS). We sought to determine the predictors and …

The sulfonylurea receptor 1 (Sur1)-regulated NCCa-ATP channel is a nonselective cation
channel that is regulated by intracellular calcium and adenosine triphosphate. The channel …

Stroke remains one of the main causes of death and disability worldwide. The challenge of
predicting stroke outcome has been traditionally assessed from a general point of view …

Acute ischemic stroke (AIS) is the fourth leading cause of death and the leading cause of
adult disability in the USA. AIS most commonly occurs when a blood vessel is obstructed …

Reperfusion therapies are the mainstay of acute ischemic stroke (AIS) treatments and
overall improve functional outcome. Among the established complications of intravenous …